Is The Trade Desk a Screaming Buy?
One factor that sets programmatic advertising platform The Trade Desk…
Sell
42
MREO Quote, Financials, Valuation and Earnings
Last price:
$2.37
Seasonality move
:
67.36%
Day range:
$2.05 - $2.34
52-week range:
$1.58 - $5.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.00x
Volume:
2.3M
Avg. volume:
1.4M
1-year change:
-10.85%
Market cap:
$365.7M
Revenue:
$10M
EPS (TTM):
-$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
$15.3M | -$0.01 | -100% | -71.23% | $7.44 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$53.6M | -$0.03 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
$2.30 | $7.44 | $365.7M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.24 | $1.71 | $61.3M | -- | $0.00 | 0% | 0.34x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.43 | $17.97 | $3.7M | -- | $0.00 | 0% | 1.49x |
|
NCNA
NuCana PLC
|
$0.86 | $104.00 | $5.2M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$58.92 | $81.00 | $5B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.724 | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 4.133 | 36.44% | 2.60x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 1.825 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | 0.371 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | 0.836 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$14.7M | -- | -- | -- | -$9.4M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Mereo BioPharma Group PLC vs. Competitors
-
Which has Higher Returns MREO or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -2303.38%. Mereo BioPharma Group PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.05 -- ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About MREO or ADAP?
Mereo BioPharma Group PLC has a consensus price target of $7.44, signalling upside risk potential of 223.34%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 616.31%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 ADAPAdaptimmune Therapeutics PLC2 3 0 -
Is MREO or ADAP More Risky?
Mereo BioPharma Group PLC has a beta of 0.650, which suggesting that the stock is 34.968% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.845, suggesting its more volatile than the S&P 500 by 184.488%.
-
Which is a Better Dividend Stock MREO or ADAP?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or ADAP?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Mereo BioPharma Group PLC's net income of -$7M is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 0.34x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$7M ADAPAdaptimmune Therapeutics PLC0.34x -- $3.2M -$74.2M
-
Which has Higher Returns MREO or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.05 -- BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About MREO or BDRX?
Mereo BioPharma Group PLC has a consensus price target of $7.44, signalling upside risk potential of 223.34%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1165.15%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is MREO or BDRX More Risky?
Mereo BioPharma Group PLC has a beta of 0.650, which suggesting that the stock is 34.968% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.705, suggesting its more volatile than the S&P 500 by 70.482%.
-
Which is a Better Dividend Stock MREO or BDRX?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BDRX?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$7M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 1.49x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$7M BDRXBiodexa Pharmaceuticals PLC1.49x -- -- --
-
Which has Higher Returns MREO or NCNA?
NuCana PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.05 -- NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About MREO or NCNA?
Mereo BioPharma Group PLC has a consensus price target of $7.44, signalling upside risk potential of 223.34%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 11993.02%. Given that NuCana PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe NuCana PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 NCNANuCana PLC0 1 0 -
Is MREO or NCNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.650, which suggesting that the stock is 34.968% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.355%.
-
Which is a Better Dividend Stock MREO or NCNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or NCNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$7M is lower than NuCana PLC's net income of -$836.1K. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$7M NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns MREO or VRNA?
Verona Pharma PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -92.29%. Mereo BioPharma Group PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.05 -- VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About MREO or VRNA?
Mereo BioPharma Group PLC has a consensus price target of $7.44, signalling upside risk potential of 223.34%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 37.48%. Given that Mereo BioPharma Group PLC has higher upside potential than Verona Pharma PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 VRNAVerona Pharma PLC5 0 0 -
Is MREO or VRNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.650, which suggesting that the stock is 34.968% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.165, suggesting its less volatile than the S&P 500 by 83.527%.
-
Which is a Better Dividend Stock MREO or VRNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or VRNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Mereo BioPharma Group PLC's net income of -$7M is higher than Verona Pharma PLC's net income of -$33.8M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$7M VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is IQQQ High Income ETF Good to Buy?
The Proshares NASDAQ-100 High Income ETF (IQQQ) is a covered…
Can Spotify Ever Become Consistently Profitable?
Spotify (NYSE:SPOT) owns more than 30% market share as the most…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 21
UnitedHealth Group [UNH] is down 5.55% over the past day.
Sell
30
MAN alert for Apr 21
ManpowerGroup [MAN] is up 0.9% over the past day.
Sell
24
GPN alert for Apr 21
Global Payments [GPN] is down 4.42% over the past day.
